Establish Diagnostic Models Based on Portal Venous Blood for Pancreatic Cancer

Launched by CHANGHAI HOSPITAL · Aug 28, 2020

Keywords

ClinConnect Summary

This clinical trial is studying new ways to diagnose pancreatic cancer by looking for specific markers in blood taken from the portal vein, which is a blood vessel that carries blood from the digestive organs to the liver. The goal is to develop better diagnostic models that can help identify cancerous growths in the pancreas. The trial is currently recruiting participants who are between 18 and 75 years old and have either been diagnosed with or are suspected to have a solid mass in their pancreas that is larger than 1 centimeter based on previous imaging tests like ultrasound, CT scans, or MRIs.

If you or someone you know is considering participating, the trial will require a signed consent form and will involve a procedure to collect blood samples. However, certain individuals may not be eligible, such as those who are pregnant, have specific blood clotting issues, or have severe heart or lung problems. Participants will help researchers gather important information that could lead to improved methods for diagnosing pancreatic cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. age 18-75 years,male or female
• • 2. diagnosis or suspection of solid pancreatic mass based on previous imaging examination (ultrasonography, CT or MRI)
• • 3. lesion diameter larger than 1 cm
• • 4. signed informed consent letter
• Exclusion Criteria:
• • 1. pregnant female
• • 2. Pancreatic cystic lesions
• • 3. Anticoagulant/antiplatelet therapy cannot be suspended
• • 4. unable or refuse to provide informed consent
• • 5. Coagulopathy (platelet count \< 50× 103/μL,international normalized ratio \> 1.5)
• • 6. Severe cardiopulmonary dysfunction that cannot tolerate intravenous anesthesia
• • 7. with history of mental disease
• • 8. other medical conditions that are not suitable for EUS-FNA